OncoMatch/Clinical Trials/NCT05716516
STUDY02001740;22SCH740: Estradiol For ER+ Advanced Breast Cancer (ESTHER)
Is NCT05716516 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Estradiol for metastatic breast cancer.
Treatment: Estradiol — Determine whether subjects harboring ESR1-mutant/amplified breast cancer have a higher rate of clinical benefit from 17b-estradiol therapy than subjects with ESR1-wild-type breast cancer
Check if I qualifyExtracted eligibility criteria
Cancer type
Breast Carcinoma
Biomarker criteria
Required: ESR1 positive
Prior therapy
Must have received: endocrine therapy (tamoxifen, aromatase inhibitor, fulvestrant) — advanced/metastatic
Received ≥1 prior line of endocrine-based therapy (e.g., including tamoxifen, aromatase inhibitors, fulvestrant, or combinations) in the advanced/metastatic setting
Cannot have received: investigational cancer therapy
Any investigational cancer therapy in the last 3 weeks
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Dartmouth-Hitchcock Medical Center · Lebanon, New Hampshire
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify